DAFTAR PUSTAKA Adisasmito, AW. dan Tumbelaka, AR. 2006, Penggunaan Antibiotik Khususnya pada Infeksi Bakteri Gram Negatif di ICU Anak RSAB Harapan Kita, Sari Pediatri, 8(2) : 127-134. American College of Clinical Pharmacy, 2005, The definition of clinical pharmacy, diakses pada 30 September 2012
American Society for Hospital-System Pharmacist. 2008, AHFS Drug Information Handbook, ASHP Inc., Bethesda MD, USA. p. 102 Ayalew, K., Sumati, N., Yuliya, Y. and Barbara, AJ. 2003, Carbapenems in Pediatrics, J Ther Drug Monit, 25(5) : 593-599. Baldwin, CM., Lyseng-Williamson, KA. and Keam, SJ. 2008, Meropenem : a review of its use in the treatment of serious bacterial infections, Drugs, 68(6) : 803-838. BNF staff. 2011, British National Formulary 61, Pharmaceutical Press, London, UK, p. 346. BNFC org. 2009, British National Formulary for children, BMJ Publishing Group Ltd., London, UK, p. 327. Bradley, JS. 1999, Carbapenems in clinical practice : a guide to their use in serious infection, Int J Antimicrob Agents, 11(2) : 93-100. Brunton, L., Lazo, JS. and Parker, KL. (ed). 2006, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition, The McGraw-Hill Comp., chapter 42. Byrne, S. 1995, Clinical evaluation of meropenem versus ceftazidime for treatment of Pseudomonas spp. infection in cystic fibrosis patients, J Antimicrob Chemother, 36 Suppl A : 135-143. Centre for Disease Control and Prevention, 2011a, ‘Delivering safe care for patients : all healthcare providers play a role’, Get Smart Programs, diakses pada 29 September 2012 Centre for Disease Control and Prevention, 2011b, ‘Resistance anywhere is resistance everywhere’, Get Smart Programs, diakses pada 29 September 2012
58
Dedic, M., Tomanovic, S. and Nikolic, L. 2005, ‘Sensitivity to meropenem and imipenem pseudomonas strains isolated from various patients material’, Abstract number : 1135_20 presented to 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5. Dellinger, R.P. et al. 2012, Surviving Sepsis Campaign : International Guidelines for Management of Severe Sepsis and Septic Shock, Critical Care Medicine and Intensive Cara Medicine, 41(2) : 580-636. Departemen Kesehatan Republik Indonesia, 2004, Keputusan Menteri Kesehatan Republik Indonesia No. 1197/MENKES/SK/X/2004 tentang Standar Pelayanan Farmasi di Rumah Sakit, Depkes RI, Jakarta, hal. 41-42. Departemen Kesehatan Republik Indonesia, 2007, Penatalaksanaan Sepsis Neonatorum, Depkes RI, Jakarta hal. 36-38. Departemen Kesehatan Republik Indonesia, 2008, Tanggung Jawab Apoteker Terhadap Keselamatan Pasien (Patient Safety ), Depkes RI, Jakarta, hal. 30. Dipiro, J.T., Talbert, H.L., Yee, G.C. Matzke, G.R., Wells, B.G. and Posey, L.M. 2011, Pharmacotherapy a Pathophysiologic Approach, 8th ed, The McGraw-Hill companies, New York, USA, chapter 116. Dwiprahasto, I. 2005, Kebijakan untuk meminimalkan risiko resistensi bakteri di unit perawatan intensif rumah sakit, JMPK, 8(40) : 177-181. Edwards, SJ., Emmas, CE. and Campbell, HE. 2005, Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infection, Curr Med Res Opin, 21(5) : 785-794. Fauziyah, S., Radji, M. dan Nurgani A. 2011, Hubungan penggunaan antibiotik pada terapi empiris dengan kepekaan bakteri di ICU RSUP Fatmawati Jakarta, Jurnal Farmasi Indonesia, 5(3) : 150-158. Fleischhack, G. 2001, Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia, J Antimicrob Chemother, 47(6) : 841-853. Gyssens, IC., Van de Brook, PJ., Kullberg, BJ. and van der Meer, JW. 1992, Optimizing Antimicrobial Therapy, J Antimicrob Chemother, 30 : 724-727. Hadi, U., Duerink, DO., Lestari, ES., Nagelke, NJ., Keuter, M., Veld, DH., et al. 2008, Audit of antibiotic prescribing in two governmental teaching hospitals in Indonesia, Clin Microb Infect, 14(7) : 698-707.
59
Hong, T., Molland, ES., Abdalhamid, B., Hanson, ND., Wang, J., Sloan, C. et al. 2005, Escherichia coli : Development of carbapenem resistance during therapy, Clin Infect Dis, 40 : 84-86. Hughes, WT., Armstrong, D., Bodey, GP. 2002, Guideline for the use of antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 34 : 730-751. Januar, MG. 2010. ‘Pengaruh Pemberian Informasi Obat Berdasarkan Beers Criteria terhadap Pola Pemberian Obat Pada Pasien Usia Lanjut Rawat Inap Penyakit Dalam di RSUD Prof. Dr. Margono Soekarjo Purwokerto Periode Mei-Agustus 2010’, Tesis, M.Sc., Universitas Gadjah Mada, Yogyakarta. Kaushal, R., Bates, DW., Abramson, EL., Soukup, JR., and Goldmann, DA. 2008, Unit-based clinical pharmacists’ prevention of serious medication errors in pedatric inpatient, Am J Health-Syst Pharm, 65 : 1254-1260. Kementerian Kesehatan RI, 2011a, ‘Program Pencegahan dan Pengendalian Infeksi Nosokomial merupakan Unsur Patient Safety’, dipresentasikan pada Seminar Sehari Patient Safety dan Pencegahan Pengendalian Infeksi diakses pada 30 September 2012, Kementerian Kesehatan RI, 2011b, Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/MENKES/PER/XII/2011 tentang Pedoman Umum Penggunaan Antibiotik, Jakarta, Kementerian Kesehatan RI, hal. 56-58. Klugman, KP. and Dagan, R. 1995, Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group, J Antimicrob Agents Chemother, 39(5) : 1140-1146. Lacy, CF., Armstrong, LL. Goldman, MP. and Lance, LL. (ed). 2009, Drug Information Handbook, 18th Edition, Lexi-Comp Inc., USA, p. 1079. MacLaren, R., Bond, CA., Martin, SJ., Fike D. 2008, Clinical and Economic Outcomes of Involving Pharmacist in The Direct Care of Critically Ill Patients with Infections, Crit Care Med, 36(12) : 3269-70. Masuda, N. and Ohya, S. 1992, Cross-Resistance to Meropenem, Cephems, and Quinolones in Pseudomonas aeruginosa, J. Antimicroblal Agents And Chemotherapy, 36(9) : 1847-1851. Nicolau, DP. 2008, Carbapenem : a potent class of antibiotics, Expert Opin Pharmacother, 9(1) : 23-37. Odio, CM., Puig, JR. and Feris, JM. 1999, Prospective, randomized, investigatorblinded studyof the efficacy and safety of meropenem vs. Cefotaxime
60
therapy in bacterial meningitis in children. Meropenem Meningitis Study Group, Pediatr Infect Dis J, 18(7) : 581-590. Ozkurt Z, Erol S, Kadanali A, Ertek M, Ozden K, Tasyaran MA. 2005, Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists, Jpn J Infect Dis, 58(6) : 338-43. Paul, M. 2006, Empirical antibiotic monotherapy for febrile neutropenia : systematic review and meta-analysis of randomized controlled trials, J Antimicrob Chemother, 57(2) : 176-189. Pamela, DS. 2011, ‘Evaluasi Kualitatif Penggunaan Antibiotika Dengan Metode Gyssens Di Ruang Kelas 3 Infeksi Departemen ilmu Kesehatan Anak RSCM Secara Prospektif’, Tesis, M.Si., Universitas Indonesia, Jakarta. Raveh, D., Muallem-zilcha, E., Greenberg, A., Wiener-well, Y., Schlesinger, Y. and Yinnon, AM. 2006, Prospective drug utilization evaluation of three broad-spectrum antimicrobials : cefepime, piperacillin-tazobactam and meropenem, Q J Med, 99 : 397-406. Sari, A., 2010. ‘Pengaruh Pelayanan Informasi Obat Terhadap Potensi Interaksi Obat Pada Pasien Rawat Inap Penyakit Dalam di RSUD Prof. Dr. Margono Soekarjo Purwokerto Periode Mei-Agustus 2010’, Tesis, M.Sc., Universitas Gadjah Mada, Yogyakarta. Schuler, D., 1995, Safety and efficacy of meropenem in hospitalized children : randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. J Antimicrob Chemother, 36 Suppl A : 99-108
Sinha, M. and Srinivasa, H. 2007, Mechanisms of resistance to carbapenems in meropenem-resistant Acinetobacter isolates from clinical samples, Indian J Med Microbiol, 25 : 121-5. Sjamsiah, S. 2007, ‘Eksistensi Farmasis di Ward. Apa dan Mengapa?’, dipresentasikan pada Seminar Nasional Farmasi Klinik : Implementasi Pelayanan Kefarmasian dalam Tatanan Klinik & Update Farmakoterapi di Surabaya, 16-17 Januari. Smith, AJ., Aronson, JK and Thomas, M. 1991, Antibiotic policies in the developing world, European Journal of Clinical Pharmacology, 41 : 85-87. Sugiyono, 2012, Statistik untuk Penelitian, Alfabeta, Bandung, hal. 143, 376.
61
Thawani, V., Gharpure, K. And Paranjpe, BD. 2006, Antibiotics : Pharmacoepidemiology of antibiotics, our experience, Regional Health Forum WHO South-East Asia Region, 2(2) : 1343. Theresia, 2011. ‘Evaluasi Kualitatif Penggunaan Antibiotik Di Departemen Ilmu Kesehatan Anak FKUI Rumah Sakit Cipto Mangunkusumo’, Tesis, M.Si., Universitas Indonesia, Jakarta. Tunkel, AR., Hartman, BJ., Kaplan, SL. 2004, Practice guideline for the management of bacterial meningitis in children. Clin Infect Dis, 39 : 12671284. Wolter, DJ., Acquazzino, D., Goering, RV., Sammut, P., Khalat, N. And Hanson, ND. 2008, Emergence of carbapenem resistance in Pseudomonas aeruginosa isolate from a patient with cystic fibrosis in the absence of carbapenem therapy, CID, 48 : 137-141. World Health Organization, 1985, The Conference of Experts on the Rational Use of Drugs, Nairobi, WHO, p. 35. World Health Organization, 2008, ‘Use of carbapenems in children’, Second Meeting of the Subcomittee of the Expert Comittee on the Selection and Use of Essential Medicines, Geneva, WHO. World Health Organization, 2012, ‘Antimicrobial resistance’, Media centre, Factsheet No. 194 diakses pada 30 September 2012
62
